par Li, Xiaoqing;Tjwa, M.;Moons, Lieve;Fons, P.;Noel, A.;Ny, A.;Zhou, J. M.;Lennartsson, J.;Ji, H.;Luttun, A.;Ponten, A.;Devy, Laetitia;Bouche, A.;Oh, H.;Manderveld, A.;Blacher, Silvia;Communi, David 
;Savy, P.;Bono, Françoise;Dewerchin, Mieke;Foidart, Jean Michel;Autiero, Monica;Herbert, Jean-Marc;Collen, Désiré;Heldin, C. H.;Eriksson, U.;Carmeliet, Peter
Référence Journal of Clinical Investigation, 115, 1, page (118-127)
Publication Publié, 2005
;Savy, P.;Bono, Françoise;Dewerchin, Mieke;Foidart, Jean Michel;Autiero, Monica;Herbert, Jean-Marc;Collen, Désiré;Heldin, C. H.;Eriksson, U.;Carmeliet, PeterRéférence Journal of Clinical Investigation, 115, 1, page (118-127)
Publication Publié, 2005
Article révisé par les pairs
| Résumé : | The angiogenic mechanism and therapeutic potential of PDGF-CC, a recently discovered member of the VEGF/PDGF superfamily, remain incompletely characterized. Here we report that PDGF-CC mobilized endothelial progenitor cells in ischemic conditions; induced differentiation of bone marrow cells into ECs; and stimulated migration of ECs. Furthermore, PDGF-CC induced the differentiation of bone marrow cells into smooth muscle cells and stimulated their growth during vessel sprouting. Moreover, delivery of PDGF-CC enhanced postischemic revascularization of the heart and limb. Modulating the activity of PDGF-CC may provide novel opportunities for treating ischemic diseases. |
